EMA to mull Tysabri-naive Gilenya PML case
This article was originally published in Scrip
A confirmed case of the rare, serious brain condition progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with Novartis's Gilenya (fingolimod) without prior treatment with Biogen's Tysabri (natalizumab) is to be considered by the European Medicine Agency's CHMP meeting this week.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.